Company: RNAC
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001453687-25-000075
Chunk: 70

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 70
---
624,000 to $642,720 for 2024, an increase in Mr. Davis’ annual base salary from $440,000 to $462,000 for 2024, an increase in Dr. Kurtoglu’s annual base salary from $402,500 to $440,000 for 2024, and an increase in Dr. Jewell’s annual base salary from $300,000 to $420,000 for 2024. All base salaries for 2024, other than with respect to Dr. Kurtoglu and Dr. Jewell, were effective as of January 1, 2024. Dr. Kurtoglu and Dr. Jewell’s base salaries for 2024 were effective March 28, 2024 and March 26, 2024, respectively.

#### Performance Bonuses
We offer our Named Executive Officers the opportunity to earn annual cash bonuses to compensate them for attaining short-term company and individual performance goals. Each Named Executive Officer has an annual target bonus that is expressed as a percentage of his annual base salary. The 2024 target bonus amount for Dr. Brunn was 55% of his base salary, and for each of Mr. Davis and Drs. Kurtoglu and Jewell was 40% of his base salary.

Our Compensation Committee, based upon the recommendation of our Chief Executive Officer, establishes Company performance goals each year and, at the completion of the year, generally determines actual bonus payouts after assessing Company performance against these goals and each Named Executive Officer’s individual performance and contributions to the Company’s achievements. For 2024, bonuses were entirely determined based on Company performance in meeting clinical, business development, manufacturing, culture and engagement, and financial goals and other corporate achievements.

The actual cash bonuses earned by the named executives for 2024 are reported under the “Non-equity incentive plan compensation” column of the 2024 Summary Compensation Table above.

#### Equity Compensation
We grant stock option awards to our Named Executive Officers as a long-term incentive component of their compensation. We have historically granted stock option awards to Named Executive Officers when they commenced employment with us and have from time to time thereafter made additional grants as, and when, our Board determined appropriate to recruit, retain or reward particular Named Executive Officers.

In connection with our initial public offering, we adopted and our stockholders approved the 2016 Plan to facilitate the grant of cash and equity incentives to our directors, employees (including our Named Executive Officers) and consultants and to enable us to obtain